Tokai Pharmaceuticals Obtains $35,500,000 Series E Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=50cdc04f-12f1-4462-8d8c-deee3027f758&Preview=1 - Date
5/15/2013 - Company Name
Tokai Pharmaceuticals - Mailing Address
One Broadway 14th Floor Cambridge , MA 02142 - Company Description
The company develops biopharmaceutical products that focus on endocrine treatment. - Website
http://www.tokaipharmaceuticals.com - Transaction Type
Venture Equity - Transaction Amount
$35,500,000 - Transaction Round
Series E - Proceeds Purposes
The proceeds will be used to expand the ongoing ARMOR2 Phase 2 clinical trial of galeterone in patients with castration-resistant prostate cancer (CRPC) and prepare for registration studies. - M&A Terms
- Venture Investor
Apple Tree Partners - Venture Investor
Novartis Venture Fund - Venture Investor
Undisclosed
